Curcumin Extract for Prevention of Type 2 Diabetes

By S. Chuengsamarn, S. Rattanamongkolgul, R. Luechapudiporn, C. Phisalaphong, Siwanon Jirawatnotai. Diabetes Care, 2012

613 citations recorded by the source corpus.

OBJECTIVE To assess the efficacy of curcumin in delaying development of type 2 diabetes mellitus (T2DM) in the prediabetic population. RESEARCH DESIGN AND METHODS This randomized, double-blinded, placebo- controlled trial included subjects (n = 240) with criteria of prediabetes. All subjects were randomly assigned to receive either curcumin or placebo capsules for 9 months. To assess the T2DM progression after curcumin treatments and to determine the number of subjects progressing to T2DM, changes in β-cell functions (homeostasis model assessment [HOMA]-β, C-peptide, and proinsulin/insulin), insulin resistance (HOMA-IR), anti-inflammatory cytokine (adiponectin), and other parameters were monitored at the baseline and at 3-, 6-, and 9-month visits during the course of intervention. RESULTS After 9 months of treatment, 16.4% of subjects in the placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in the curcumin-treated group. In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (61.58 vs. 48.72; P < 0.01) and lower C-peptide (1.7 vs. 2.17; P < 0.05). The curcumin-treated group showed a lower level of HOMA-IR (3.22 vs. 4.04; P < 0.001) and higher adiponectin (22.46 vs. 18.45; P < 0.05) when compared with the placebo group. CONCLUSIONS A 9-month curcumin intervention in a prediabetic population significantly lowered the number of prediabetic individuals who eventually developed T2DM. In addition, the curcumin treatment appeared to improve overall function of β-cells, with very minor adverse effects. Therefore, this study demonstrated that the curcumin intervention in a prediabetic population may be beneficial.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/94e98b04cb9e711cebb58055f9ca1e9acc6b7a4b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

Bharat B. Aggarwal

In Epidemiology

Bharat B. Aggarwal

In Molecular Medicine

Citations in the corpus

Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases (2017, background): “…2008 3 × 500 mg·day 1; 2 monthsc 40 Attenuated proteinuria, TGFβ and IL-8 Khajehdehi et al., 2011 1.5 g·day 1; 3, 6 and 9 months 240 Safe, well tolerated and efficacious Chuengsamarn et al., 2012 300 mg·day 1; 3 months 100 Effective, decreased serum A-FABP level Na et al., 2014 2 × 750 mg·day 1; 6…”
Curcumin: A Review of Its’ Effects on Human Health (2017, background): “Curcumin has been shown to attenuate several aspects of MetS by improving insulin sensitivity [43,44], suppressing adipogenesis [45], and reducing elevated blood pressure [46], inflammation [47], and oxidative stress [48,49].”